Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 8/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | KDM6A | O15550 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433583 | 1.00 | EIF2AK4 (0.37) | EIF2AK4MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL11978261 | 0.94 | RET (0.37) | EIF2AK4MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL11898914 | 0.91 | MAPT (0.36) | MAPTGPR119PIM1PIM3PIM2 | |
| SCHEMBL4433671 | 0.91 | MAPT (0.36) | MAPTGPR119PIM1PIM3PIM2 | |
| SCHEMBL1710280 | 0.91 | MAPT (0.36) | MAPTGPR119PIM1PIM3PIM2 | |
| SCHEMBL13707585 | 0.86 | EIF2AK4 (0.40) | EIF2AK4MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL13456795 | 0.86 | EIF2AK4 (0.40) | EIF2AK4MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL4118695 | 0.86 | MAPT (0.38) | EIF2AK4CKS1BSKP1SKP2KDM4D | |
| SCHEMBL4132594 | 0.86 | MAPT (0.38) | EIF2AK4CKS1BSKP1SKP2KDM4D | |
| SCHEMBL30628534 | 0.85 | MAP4K4 (0.35) | EIF2AK4MAP4K4KDM4DMAPTPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | EIF2AK4 368/4885MAP4K4 50/4885CKS1B 216/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | EIF2AK4 401/4885MAP4K4 85/4885CKS1B 178/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | EIF2AK4 368/4885MAP4K4 50/4885CKS1B 216/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | EIF2AK4 401/4885MAP4K4 85/4885CKS1B 178/4885 |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | EIF2AK4 512/4885MAP4K4 105/4885CKS1B 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.